What is Sales and Marketing Strategy of Coherus Biosciences Company?

Coherus Biosciences Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the Sales and Marketing Strategy of Coherus Biosciences?

Coherus BioSciences has significantly shifted its sales and marketing strategy, moving from a biosimilar focus to becoming a commercial-stage innovative oncology company. This transformation is marked by the divestiture of its biosimilar portfolio, including the UDENYCA franchise, to concentrate on novel cancer treatments.

This strategic pivot has necessitated a complete overhaul of how the company reaches customers, its marketing tactics, brand positioning, and what makes its recent campaigns stand out. The goal is to maximize revenue from its oncology assets and fund its innovative pipeline.

The company's sales and marketing strategy now centers on its innovative immuno-oncology portfolio, particularly its next-generation PD-1 inhibitor. This contrasts sharply with its earlier approach, which focused on providing cost-effective alternatives to established biologic drugs, such as UDENYCA. For a deeper understanding of its market positioning, consider the Coherus Biosciences BCG Matrix.

Coherus BioSciences has significantly reshaped its sales channels, transitioning from a broad biosimilar distribution model to a focused direct sales approach for its innovative oncology treatments. This strategic pivot emphasizes direct engagement with healthcare professionals, particularly oncologists and medical institutions, to effectively promote and maximize the uptake of products like LOQTORZI. The company's Coherus Biosciences sales strategy now prioritizes a dedicated sales force targeting key accounts within the oncology sector to drive revenue growth.

Direct Oncology Sales Force

The core of Coherus BioSciences' current sales strategy involves a direct sales force. This team is specifically trained to engage with oncologists and healthcare institutions, ensuring targeted promotion of their innovative oncology products.

Divestiture of Biosimilar Portfolio

Coherus has strategically divested its biosimilar assets to concentrate resources on its oncology pipeline. This includes the sale of UDENYCA in April 2025, CIMERLI in January 2024 for $170 million, and YUSIMRY in June 2024 for $40 million.

Focus on Oncology Pipeline

The company's business strategy is now centered on maximizing sales for LOQTORZI and advancing its internal oncology pipeline. This shift moves away from a multi-product biosimilar approach to a concentrated effort on high-potential oncology treatments.

Partnership Strategy Evolution

While past biosimilar commercialization involved partnerships, the current Coherus Biosciences partnership strategy in sales focuses on evaluating LOQTORZI with novel cancer agents for label expansions, indicating a selective approach to collaborations.

LOQTORZI Performance and Future Collaborations

LOQTORZI has demonstrated promising early performance, with net product sales reaching $7.3 million in Q1 2025. Patient demand for the product saw a growth of over 15% compared to the previous quarter, signaling positive market reception.

• LOQTORZI net product sales in Q1 2025: $7.3 million.
• Patient demand for LOQTORZI increased by over 15% from Q4 2024 to Q1 2025.
• Coherus plans additional partnerships in 2025 to explore LOQTORZI in combination therapies.
• The company's strategic focus is on its oncology pipeline, supported by its Revenue Streams & Business Model of Coherus Biosciences.

Coherus Biosciences SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Coherus BioSciences' marketing tactics are centered on building awareness and driving sales for its innovative oncology products, particularly LOQTORZI. The company prioritizes in-depth medical education for prescribers, especially oncologists, reflecting the specialized nature of its treatments. This approach is crucial for market penetration and establishing its position in the oncology landscape.

Medical Education and Prescriber Engagement

Coherus BioSciences focuses on educating healthcare professionals, particularly oncologists, about its innovative oncology treatments. This direct engagement is key to driving adoption and ensuring appropriate use of its products.

Digital Presence and Branding

The company has invested in its digital infrastructure, including website design and social media channels, to reflect its new focus on immuno-oncology. This digital transformation aims to enhance brand perception and communication.

Targeted Sales Force Efforts

Coherus's sales team actively educates customers on treatment guidelines for LOQTORZI. They also address the off-label use of competitor products, aiming to highlight the advantages and appropriate indications for their own offerings.

Investor and Analyst Communications

Traditional marketing efforts include presentations to investors and analysts, where the company provides updates on financial performance and business developments. These forums are vital for maintaining stakeholder confidence and transparency.

Strategic Market Focus

Following the divestiture of biosimilars, Coherus has sharpened its focus on maximizing revenue from LOQTORZI. This strategic shift implies a highly segmented and targeted approach to reaching oncology specialists.

Pipeline Development Emphasis

Marketing efforts are also aligned with pipeline development, indicating a long-term strategy to build and expand its presence in the oncology market. This includes efforts to gain market share for its innovative products.

The Coherus Biosciences business strategy has significantly evolved, with a pronounced shift towards innovative oncology, particularly with the product LOQTORZI. This pivot has reshaped its marketing tactics, moving away from a broader biosimilar focus to a concentrated effort on penetrating the oncology market. The company's digital marketing approach includes enhancing its online presence through website redesign and social media channel development, reflecting its immuno-oncology focus. While specific data on customer segmentation and personalization is not extensively detailed, the intense focus on LOQTORZI's commercial success suggests a sophisticated, data-driven approach to identifying and engaging key prescribers. The sales force effectiveness is a critical component, tasked with educating the market on LOQTORZI's benefits and differentiating it from competitors. This aligns with the broader Marketing Strategy of Coherus Biosciences, which emphasizes targeted outreach and value proposition communication.

Key Marketing Tactics for LOQTORZI

Coherus BioSciences employs a multi-faceted marketing strategy to drive the adoption of LOQTORZI, its key oncology product. This includes direct engagement with healthcare providers and a strong digital presence.

• In-depth medical education for oncologists and other prescribers.
• Targeted sales force efforts to educate on treatment guidelines and competitive differentiation.
• Digital marketing initiatives including website and social media enhancements.
• Investor and analyst presentations to communicate business progress and financial performance.
• Focus on market penetration and pipeline development within the oncology sector.

Coherus Biosciences PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Coherus BioSciences has strategically repositioned its brand to exclusively focus on innovative oncology, rebranding to Coherus Oncology. This shift highlights its dedication to developing cutting-edge immuno-oncology medicines and leverages its established commercial expertise in the oncology sector.

Oncology Focus

The company's core identity now centers on transforming cancer patient lives through advanced immuno-oncology therapeutics. This renewed emphasis is supported by a comprehensive rebrand, including a new logo and visual identity.

Pipeline and Commercial Strength

Coherus differentiates itself by showcasing a robust pipeline of next-generation immunotherapies. Its proven commercial capabilities in oncology are a key asset in its market strategy.

Target Audience Engagement

The brand appeals to healthcare providers and oncologists by emphasizing innovation and highlighting specific product successes. This includes promoting LOQTORZI as a unique treatment option.

Strategic Divestitures

Recent divestitures of its biosimilar portfolio reinforce the company's commitment to brand consistency and a focused business strategy. This move aims for a more concentrated and financially robust market position.

The brand's messaging is meticulously crafted to resonate with healthcare professionals, emphasizing a commitment to scientific advancement and patient outcomes in oncology. The strategic decision to divest its biosimilar portfolio, a move that significantly reshaped the Coherus Biosciences product portfolio, underscores a clear intent to concentrate resources and expertise on its immuno-oncology pipeline. This allows for a more streamlined Coherus Biosciences sales strategy, directly targeting the needs of cancer specialists. The company's marketing campaigns are designed to educate and engage oncologists, showcasing the potential of its innovative therapies. This approach is crucial for establishing a strong Coherus Biosciences brand positioning in a highly competitive market. Understanding the Competitors Landscape of Coherus Biosciences is vital for appreciating the strategic nuances of their market entry and growth plans.

Oncology Specialization

The rebranding to Coherus Oncology signals a definitive pivot towards specialized cancer treatments. This focus allows for targeted Coherus Biosciences marketing strategy efforts.

Innovation in Immuno-Oncology

Emphasis is placed on developing next-generation immunotherapies. This commitment to innovation is a cornerstone of the Coherus Biosciences business strategy.

Product Differentiation

Highlighting unique treatments like LOQTORZI for nasopharyngeal carcinoma serves as a key differentiator. This supports the Coherus Biosciences sales tactics and market penetration.

Commercial Acumen

Leveraging proven commercial capabilities in oncology is essential. This ensures effective Coherus Biosciences sales force effectiveness and market reach.

Strategic Portfolio Management

Divesting non-core assets strengthens the focus on oncology. This strategic move impacts Coherus Biosciences market share and future growth drivers.

Patient Access and Support

Coherus Biosciences patient access programs are integral to its marketing. These programs aim to ensure patients can benefit from innovative treatments.

Coherus Biosciences Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Coherus BioSciences has recently pivoted its sales and marketing strategy to focus on innovative oncology, moving away from its biosimilar offerings. This strategic shift is reflected in its key campaigns, prioritizing the commercialization of its next-generation PD-1 inhibitor.

UDENYCA Autoinjector Launch Campaign (Historical)

Launched in May 2023, this campaign focused on enhancing patient access and convenience for UDENYCA. It saw significant success, with unit demand increasing by 129% in Q4 2023 and securing orders from over 727 accounts.

LOQTORZI Commercialization Campaign (2024-2025)

This is the company's defining campaign, centered on LOQTORZI's market introduction following its October 2023 FDA approval. The campaign aims to establish LOQTORZI as the leading treatment for nasopharyngeal carcinoma.

LOQTORZI Market Penetration Strategy

The strategy involves a dedicated sales team and digital promotions to educate healthcare providers on LOQTORZI's clinical data. The goal is to encourage a shift from off-label use of competitor products to LOQTORZI, particularly for its approved indication.

Pipeline Integration and Label Expansion

Coherus is actively exploring partnerships and combinations with pipeline assets like casdozokitug and CHS-114. This initiative aims to broaden LOQTORZI's approved indications and further drive sales growth.

The broader Coherus Biosciences business strategy includes divesting its biosimilar franchises, such as CIMERLI, YUSIMRY, and UDENYCA, throughout 2024-2025. These divestitures are projected to generate hundreds of millions of dollars, providing crucial funding for its innovative oncology pipeline and ensuring a cash runway of over two years. This aligns with the overall Growth Strategy of Coherus Biosciences, focusing resources on high-potential oncology assets.

UDENYCA Sales Performance

For the full year 2024, UDENYCA net product sales reached $206.0 million, a 62% increase from FY 2023, despite a temporary supply interruption.

LOQTORZI Q1 2025 Performance

LOQTORZI generated $7.3 million in net product sales for Q1 2025, with patient demand showing growth exceeding 15% compared to Q4 2024.

Strategic Divestiture Proceeds

The divestment of biosimilar franchises is expected to yield hundreds of millions of dollars, bolstering the company's financial position for its oncology focus.

LOQTORZI Market Positioning

LOQTORZI is positioned as the sole FDA-approved treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma, a key differentiator in its marketing efforts.

Sales Force Focus

A specialized sales team is dedicated to promoting LOQTORZI, emphasizing its data and guideline support to physicians.

Digital Marketing Approach

Digital promotions play a crucial role in educating customers and driving awareness for LOQTORZI's benefits and clinical profile.

Coherus Biosciences Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔